These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
519 related articles for article (PubMed ID: 33923759)
21. Grade 3 well-differentiated neuroendocrine tumor of the rectum: a case report. Ito M; Hirano Y; Isii T; Kondo H; Wang L; Asari M; Obara N; Yamaguchi S Surg Case Rep; 2020 Jun; 6(1):130. PubMed ID: 32533349 [TBL] [Abstract][Full Text] [Related]
31. Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis. Laffi A; Spada F; Bagnardi V; Frassoni S; Pisa E; Rubino M; Barberis M; Fazio N J Endocrinol Invest; 2022 Feb; 45(2):317-325. PubMed ID: 34282554 [TBL] [Abstract][Full Text] [Related]
32. Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review. Zappi A; Persano I; Galvani L; Parlagreco E; Andrini E; Campana D; Brizzi MP; Lamberti G; La Salvia A J Clin Med; 2023 Jan; 12(2):. PubMed ID: 36675645 [TBL] [Abstract][Full Text] [Related]
33. Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3. Hinterleitner M; Pfeiffer R; Trautwein NF; Sipos B; Singer S; Nadalin S; Königsrainer A; Lauer UM; la Fougère C; Zender L; Hinterleitner C Front Endocrinol (Lausanne); 2023; 14():1285529. PubMed ID: 38260136 [TBL] [Abstract][Full Text] [Related]
34. Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database. Punekar SR; Kaakour D; Masri-Lavine L; Hajdu C; Newman E; Becker DJ Am J Clin Oncol; 2020 Dec; 43(12):846-849. PubMed ID: 32910023 [TBL] [Abstract][Full Text] [Related]
35. Treatment outcomes of advanced digestive well-differentiated grade 3 NETs. de Mestier L; Lamarca A; Hernando J; Zandee W; Alonso-Gordoa T; Perrier M; Walenkamp AM; Chakrabarty B; Landolfi S; Van Velthuysen MF; Kats-Ugurlu G; Caminoa A; Ronot M; Manoharan P; Garcia-Alvarez A; Brabander T; García Gómez-Muriel MI; Cadiot G; Couvelard A; Capdevila J; Pavel ME; Cros J Endocr Relat Cancer; 2021 Jun; 28(8):549-561. PubMed ID: 34061764 [TBL] [Abstract][Full Text] [Related]
36. Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma - retrospective analysis. Rogowski W; Wachuła E; Gorzelak A; Lebiedzińska A; Sulżyc-Bielicka V; Iżycka-Świeszewska E; Żołnierek J; Kos-Kudła B Endokrynol Pol; 2019; 70(4):313-317. PubMed ID: 30843182 [TBL] [Abstract][Full Text] [Related]
37. Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas. Frizziero M; Spada F; Lamarca A; Kordatou Z; Barriuso J; Nuttall C; McNamara MG; Hubner RA; Mansoor W; Manoharan P; Fazio N; Valle JW Neuroendocrinology; 2019; 109(2):100-112. PubMed ID: 30703770 [TBL] [Abstract][Full Text] [Related]
38. FOLFOX-bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors. Lacombe C; Perrier M; Hentic O; Brixi H; De Rycke O; Cros J; Rebours V; Cadiot G; Ruszniewski P; de Mestier L J Neuroendocrinol; 2023 Jan; 35(1):e13227. PubMed ID: 36599808 [TBL] [Abstract][Full Text] [Related]
39. Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms. Morken S; Langer SW; Sundlöv A; Vestermark LW; Ladekarl M; Hjortland GO; Svensson JB; Tabaksblat EM; Haslerud TM; Assmus J; Detlefsen S; Couvelard A; Perren A; Sorbye H Br J Cancer; 2023 Dec; 129(12):1930-1939. PubMed ID: 37872405 [TBL] [Abstract][Full Text] [Related]
40. Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor. de Mestier L; Walter T; Evrard C; de Boissieu P; Hentic O; Cros J; Tougeron D; Lombard-Bohas C; Rebours V; Hammel P; Ruszniewski P Neuroendocrinology; 2020; 110(1-2):83-91. PubMed ID: 31071715 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]